PP47 First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group.

MLA

Minegishi, Y., et al. “PP47 First Line Gefitinib versus First Line Chemotherapy by Carboplatin plus Paclitaxel in Non-Small Cell Lung Cancer Patients with EGFR Mutations: A Phase III Study (002) by North East Japan Gefitinib Study Group.” EJC Supplements, vol. 7, no. 4, Dec. 2009, p. 25. EBSCOhost, https://doi.org/10.1016/S1359-6349(09)72190-1.

APA

Minegishi, Y., Inoue, A., Kobayashi, K., Gemma, A., Maemondo, M., Oizumi, S., Saijo, Y., Morita, S., Hagiwara, K., & Nukiwa, T. (2009). PP47 First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. EJC Supplements, 7(4), 25. https://doi.org/10.1016/S1359-6349(09)72190-1

Chicago

Minegishi, Y., A. Inoue, K. Kobayashi, A. Gemma, M. Maemondo, S. Oizumi, Y. Saijo, S. Morita, K. Hagiwara, and T. Nukiwa. 2009. “PP47 First Line Gefitinib versus First Line Chemotherapy by Carboplatin plus Paclitaxel in Non-Small Cell Lung Cancer Patients with EGFR Mutations: A Phase III Study (002) by North East Japan Gefitinib Study Group.” EJC Supplements 7 (4): 25. doi:10.1016/S1359-6349(09)72190-1.